Overview

The marketing authorisation for Zontivity has been withdrawn at the request of the marketing authorisation holder.

български (BG) (633.29 KB - PDF)

View

español (ES) (547.87 KB - PDF)

View

čeština (CS) (614.5 KB - PDF)

View

dansk (DA) (545.41 KB - PDF)

View

Deutsch (DE) (550.79 KB - PDF)

View

eesti keel (ET) (544.17 KB - PDF)

View

ελληνικά (EL) (636.04 KB - PDF)

View

français (FR) (549.89 KB - PDF)

View

hrvatski (HR) (573.91 KB - PDF)

View

italiano (IT) (545.6 KB - PDF)

View

latviešu valoda (LV) (614.26 KB - PDF)

View

lietuvių kalba (LT) (574.98 KB - PDF)

View

magyar (HU) (611.07 KB - PDF)

View

Malti (MT) (617.97 KB - PDF)

View

Nederlands (NL) (547.11 KB - PDF)

View

polski (PL) (612.51 KB - PDF)

View

português (PT) (548.44 KB - PDF)

View

română (RO) (575.49 KB - PDF)

View

slovenčina (SK) (612.69 KB - PDF)

View

slovenščina (SL) (607.05 KB - PDF)

View

Suomi (FI) (545.31 KB - PDF)

View

svenska (SV) (546.74 KB - PDF)

View

Product information

български (BG) (1.9 MB - PDF)

View

español (ES) (1.26 MB - PDF)

View

čeština (CS) (1.65 MB - PDF)

View

dansk (DA) (1.33 MB - PDF)

View

Deutsch (DE) (1.34 MB - PDF)

View

eesti keel (ET) (1.15 MB - PDF)

View

ελληνικά (EL) (1.99 MB - PDF)

View

français (FR) (1.22 MB - PDF)

View

hrvatski (HR) (1.31 MB - PDF)

View

íslenska (IS) (1.27 MB - PDF)

View

italiano (IT) (1.32 MB - PDF)

View

latviešu valoda (LV) (1.68 MB - PDF)

View

lietuvių kalba (LT) (1.29 MB - PDF)

View

magyar (HU) (1.72 MB - PDF)

View

Malti (MT) (1.81 MB - PDF)

View

Nederlands (NL) (1.29 MB - PDF)

View

norsk (NO) (1.26 MB - PDF)

View

polski (PL) (1.8 MB - PDF)

View

português (PT) (1.18 MB - PDF)

View

română (RO) (1.33 MB - PDF)

View

slovenčina (SK) (1.6 MB - PDF)

View

slovenščina (SL) (1.64 MB - PDF)

View

Suomi (FI) (1.3 MB - PDF)

View

svenska (SV) (1.15 MB - PDF)

View

Latest procedure affecting product information: II/0005

29/07/2016

icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (517.85 KB - PDF)

View

español (ES) (479.2 KB - PDF)

View

čeština (CS) (495.84 KB - PDF)

View

dansk (DA) (478.74 KB - PDF)

View

Deutsch (DE) (476.03 KB - PDF)

View

eesti keel (ET) (476.56 KB - PDF)

View

ελληνικά (EL) (513.72 KB - PDF)

View

français (FR) (479.35 KB - PDF)

View

hrvatski (HR) (493.84 KB - PDF)

View

íslenska (IS) (476.36 KB - PDF)

View

italiano (IT) (475.94 KB - PDF)

View

latviešu valoda (LV) (509.36 KB - PDF)

View

lietuvių kalba (LT) (497.93 KB - PDF)

View

magyar (HU) (495.04 KB - PDF)

View

Malti (MT) (503.26 KB - PDF)

View

Nederlands (NL) (477.88 KB - PDF)

View

norsk (NO) (475.54 KB - PDF)

View

polski (PL) (506.04 KB - PDF)

View

português (PT) (478.9 KB - PDF)

View

română (RO) (493.84 KB - PDF)

View

slovenčina (SK) (497.53 KB - PDF)

View

slovenščina (SL) (496.4 KB - PDF)

View

Suomi (FI) (480.42 KB - PDF)

View

svenska (SV) (476.2 KB - PDF)

View

Product details

Name of medicine
Zontivity
Active substance
vorapaxar sulfate
International non-proprietary name (INN) or common name
vorapaxar
Therapeutic area (MeSH)
Myocardial Infarction
Anatomical therapeutic chemical (ATC) code
B01

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Zontivityis indicated for the reduction of atherothrombotic events in adult patients with

- a history of myocardial infarction (MI), ,co-administered with acetylsalicylic acid (ASA) and, where appropriate, clopidogrel; or

- symptomatic peripheral arterial disease

(PAD), co-administered with acetylsalicylic acid (ASA) or, where appropriate, clopidogrel.

Authorisation details

EMA product number
EMEA/H/C/002814
Marketing authorisation holder
Merck Sharp Dohme Limited

Hertford Road
EN11 9BU Hoddesdon
United Kingdom

Marketing authorisation issued
19/01/2015
Revision
2

Assessment history

This page was last updated on

Share this page